Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) Announces Estimated 2025 Annual Results

Bulletin Express01-29

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) released an inside information announcement disclosing preliminary estimates for its annual results for the year ending December 31, 2025.

According to the announcement, revenue is projected to range from RMB1,368.81 million to RMB1,388.81 million, representing a year-on-year increase of approximately 39.61% to 41.65%. Net profit attributable to owners is expected to be between RMB162.43 million and RMB182.43 million, marking a year-on-year growth of around 384.26% to 443.88%. After deducting non-recurring items, net profit attributable to owners is anticipated to reach RMB104.92 million to RMB124.92 million, reflecting an increase of about 356.81% to 443.88% compared with the previous year.

The announcement notes that the expansion of overseas markets, alongside a recovery in the domestic biopharmaceutical industry, contributed to a rapid increase in revenue. A high-entry-barrier technological edge supported strong gross margins, and lean management initiatives improved overall operating efficiency, leading to significantly higher profitability.

All figures mentioned are based on preliminary calculations under the China Accounting Standards for Business Enterprises and have not been audited. Official results will be finalized in the 2025 annual report, and investors are advised to exercise caution in interpreting the preliminary data.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1150439888?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1150439888","market":"us","top_or_hot":-1,"title":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) Announces Estimated 2025 Annual Results","media":"Bulletin Express","content":"<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) released an inside information announcement disclosing preliminary estimates for its annual results for the year ending December 31, 2025.</p>\n<p>According to the announcement, revenue is projected to range from RMB1,368.81 million to RMB1,388.81 million, representing a year-on-year increase of approximately 39.61% to 41.65%. Net profit attributable to owners is expected to be between RMB162.43 million and RMB182.43 million, marking a year-on-year growth of around 384.26% to 443.88%. After deducting non-recurring items, net profit attributable to owners is anticipated to reach RMB104.92 million to RMB124.92 million, reflecting an increase of about 356.81% to 443.88% compared with the previous year.</p>\n<p>The announcement notes that the expansion of overseas markets, alongside a recovery in the domestic biopharmaceutical industry, contributed to a rapid increase in revenue. A high-entry-barrier technological edge supported strong gross margins, and lean management initiatives improved overall operating efficiency, leading to significantly higher profitability.</p>\n<p>All figures mentioned are based on preliminary calculations under the China Accounting Standards for Business Enterprises and have not been audited. Official results will be finalized in the 2025 annual report, and investors are advised to exercise caution in interpreting the preliminary data.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) Announces Estimated 2025 Annual Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) Announces Estimated 2025 Annual Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-01-29 16:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) released an inside information announcement disclosing preliminary estimates for its annual results for the year ending December 31, 2025.</p>\n<p>According to the announcement, revenue is projected to range from RMB1,368.81 million to RMB1,388.81 million, representing a year-on-year increase of approximately 39.61% to 41.65%. Net profit attributable to owners is expected to be between RMB162.43 million and RMB182.43 million, marking a year-on-year growth of around 384.26% to 443.88%. After deducting non-recurring items, net profit attributable to owners is anticipated to reach RMB104.92 million to RMB124.92 million, reflecting an increase of about 356.81% to 443.88% compared with the previous year.</p>\n<p>The announcement notes that the expansion of overseas markets, alongside a recovery in the domestic biopharmaceutical industry, contributed to a rapid increase in revenue. A high-entry-barrier technological edge supported strong gross margins, and lean management initiatives improved overall operating efficiency, leading to significantly higher profitability.</p>\n<p>All figures mentioned are based on preliminary calculations under the China Accounting Standards for Business Enterprises and have not been audited. Official results will be finalized in the 2025 annual report, and investors are advised to exercise caution in interpreting the preliminary data.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02315","symbol_name":"百奥赛图-B","start_time":0,"source_url":"","article_id":"1150439888","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1150439888","pubTimestamp":1769676461,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) released an inside information announcement disclosing preliminary estimates for its annual results for the year ending December 31,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02315":"百奥赛图-B"},"translate_title":"百奥赛图药业（北京）股份有限公司（股份代号：2315）公布2025年度预计业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02315":1},"content_text":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Stock Code: 2315) released an inside information announcement disclosing preliminary estimates for its annual results for the year ending December 31, 2025.\nAccording to the announcement, revenue is projected to range from RMB1,368.81 million to RMB1,388.81 million, representing a year-on-year increase of approximately 39.61% to 41.65%. Net profit attributable to owners is expected to be between RMB162.43 million and RMB182.43 million, marking a year-on-year growth of around 384.26% to 443.88%. After deducting non-recurring items, net profit attributable to owners is anticipated to reach RMB104.92 million to RMB124.92 million, reflecting an increase of about 356.81% to 443.88% compared with the previous year.\nThe announcement notes that the expansion of overseas markets, alongside a recovery in the domestic biopharmaceutical industry, contributed to a rapid increase in revenue. A high-entry-barrier technological edge supported strong gross margins, and lean management initiatives improved overall operating efficiency, leading to significantly higher profitability.\nAll figures mentioned are based on preliminary calculations under the China Accounting Standards for Business Enterprises and have not been audited. Official results will be finalized in the 2025 annual report, and investors are advised to exercise caution in interpreting the preliminary data.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1150439888","isCrawlerRequest":true}